Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

16.84 -0.18 (-1.06%)
Streaming Delayed Price Updated: 1:46 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
From Teva Pharmaceutical Industries Ltd; Medincell
Via GlobeNewswire
Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity
Via Benzinga
Teva Pharmaceutical Indus Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025. 
Via Benzinga
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
Via Benzinga
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
From Teva Pharmaceutical Industries Ltd; Alvotech
Via GlobeNewswire
Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4
Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent... 
Via Benzinga
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
Via The Motley Fool
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
MarketBeat Week in Review – 02/03 - 02/07
Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets. 
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Interest Rates Tariff
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. 
Via The Motley Fool
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp? 
Via MarketBeat
NVIDIA, Teva Pharmaceutical And UPS Are Among Top Large Cap Losers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
Discover the latest trends with last week's worst-performing large-cap stocks, including Manhattan Associates' steep decline following reduced financial guidance and the broader impact of China's... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Teva Pharmaceutical Stock Is Sinking Today
Via The Motley Fool
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
TEVA earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet
Via Benzinga
Exposures Fossil Fuels
Stocks Scatter As Investors Prepare For Fed Remarks
Stocks are mixed this afternoon, as investors await an interest rate update from the Federal Reserve's first policy meeting of 2025. 
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Interest Rates
Nasdaq Down Over 100 Points; Corning Posts Upbeat Earnings
Via Benzinga
Stocks Tick Down Ahead Of Fed Meeting, Nvidia Jitters Resume, Trump Media Rallies: What's Driving Markets Wednesday?
Caution dominates Wednesday's midday trading session in New York as investors anxiously await the Federal Open Market Committee decision at 2 p.m. ET. 
Via Benzinga
Topics Economy Government
Exposures Interest Rates Political
Teva Pharmaceutical Posts Lower Revenue. Stock Slips.
Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue. 
Via Investor's Business Daily
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,... 
Via Benzinga
Manhattan Associates, LendingClub And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.